AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02325960
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
Trial: NCT00875030
Drug: artesunate sachets
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose 50 mg (2 X 25 mg) artesunate sachets
Trial: NCT00834522
Drug: Granisetron hydrochloride 1 mg tablets
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 1 mg, single dose non-fasting
Trial: NCT02738970
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
Trial: NCT02738970
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
Trial: NCT00905346
Drug: Topiramate 25 mg Capsules
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate Capsules 2 x 25 mg
Trial: NCT02735395
Drug: Metronidazole 250 (7 days)
RxNorm normalized name: metronidazole 250 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Trial: NCT02735395
Drug: Metronidazole 400 (7 days)
RxNorm normalized name: metronidazole 400 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Trial: NCT02735395
Drug: Metronidazole 250 (14 days)
RxNorm normalized name: metronidazole 250 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Trial: NCT02735395
Drug: Metronidazole 400 (14 days)
RxNorm normalized name: metronidazole 400 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Trial: NCT02735395
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
Trial: NCT00197639
Drug: Ritonavir-boosted indinavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03878446
Drug: Somapacitan
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan injected under the skin once a week.
Trial: NCT02284984
Drug: Rituximab with belimumab
RxNorm normalized name: Belimumab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
Trial: NCT01834014
Drug: L-OHP
RxNorm normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01751048
Drug: SE
RxNorm normalized name: Ser
DrugBank: Serine (DB00133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
Trial: NCT03703102
Drug: KHK4083
RxNorm normalized name: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-OX40 Monoclonal Antibody KHK4083
Trial: NCT00039585
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02458963
Drug: Gonadotropin
RxNorm normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
Trial: NCT00234689
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01041482
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib 400mg twice daily
Trial: NCT00428142
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3mg/m2 days 1 \& 8
Trial: NCT00428142
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/m2 days 1-5
Trial: NCT00428142
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4mg/m2 day 1 (dose capped at 2mg)
Trial: NCT01356407
Drug: PICOPREP
DrugBank: Picosulfuric acid (DB09268)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02162836
Drug: JNJ-56021927
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
Trial: NCT02111161
Drug: IVIG (Privigen)
RxNorm normalized name: Privigen
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 25 g IVIG (250 ml)
Trial: NCT04417036
Drug: BAY1097761 Active Dose 1
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a lower dose ADM by inhalation
Trial: NCT04417036
Drug: BAY1097761 Active Dose 2
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a higher dose ADM by inhalation
Trial: NCT04585464
Drug: EDG-5506
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDG-5506 is administered orally as a single dose or once daily
Trial: NCT01197521
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fostamatinib 100 mg twice daily
Trial: NCT01197521
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fostamatinib 100 mg twice daily/150 mg once daily
Trial: NCT01197521
Drug: placebo, fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
Trial: NCT01245582
Drug: oxaliplatin (SR96669)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:injection~Route of administration: intravenous
Trial: NCT01245582
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT00405067
Drug: BMS-201038 (AEGR-733)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00405067
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00944424
Drug: Docetaxel + High dose Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + High dose Vitamin D2
Trial: NCT00944424
Drug: Docetaxel + Standard dose Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel + Standard dose Vitamin D2
Trial: NCT02192203
Drug: Menthol Only Gel
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% menthol
Trial: NCT03767075
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg, administered IV, once every 3 weeks
Trial: NCT03767075
Drug: Futibatinib
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg administered orally, once daily (QD) continuously in 28-day cycles.
Trial: NCT03767075
Drug: Amivantamab
RxNorm normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Trial: NCT03462576
Drug: Emricasan
RxNorm normalized name: Emricasan
DrugBank: Emricasan (DB05408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug for NASH treatment in Main Conatus protocol
Trial: NCT06385483
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03201458
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03201458
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02092012
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
Trial: NCT00433108
Drug: Mitoquinone mesylate (MitoQ)
RxNorm normalized name: mesylate
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00300664
Drug: Human Growth hormone
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03962101
Drug: OPC-61815 injection
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
Trial: NCT03137368
Drug: Exemestane Tablets
RxNorm normalized name: Exemestane Tablets
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug therapy
Trial: NCT01834014
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT02817321
Drug: single dose ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed
Trial: NCT02817321
Drug: continuously infusion of ropivacaine
RxNorm normalized name: Uniphyllin Continus
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose
Trial: NCT02817321
Drug: Morphine given as IPCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Trial: NCT00518154
Drug: Pyridostigmine tablets
RxNorm normalized name: pyridostigmine Oral Tablet
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 30mg tid PO for 12 weeks
Trial: NCT01468584
Drug: MP-424 (generic name:Telaprevir)
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750mg q8h for 12 weeks
Trial: NCT01468584
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 - 1000 mg/day based on body weight for 24 weeks
Trial: NCT01468584
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5mcg/kg/week for 24 weeks
Trial: NCT01536600
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The insulin dose and regimen was individualised at the physician's discretion
Trial: NCT01867281
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03137368
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug therapy
Trial: NCT01044771
Drug: change from tenofovir to raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
Trial: NCT00431197
Drug: Ketoconazole, Dexamethesone, Androgel,GnRH
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01433497
Drug: Masitinib
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03853785
Drug: Topical Podophyllin
RxNorm normalized name: podophyllin Topical Solution
DrugBank: Podophyllin (DB09094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
Trial: NCT00271596
Drug: 20mg daily citalopram
RxNorm normalized name: citalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
Trial: NCT00892385
Drug: Methoxyamine
RxNorm normalized name: Methoxyamine
DrugBank: Methoxyamine (DB06328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
Trial: NCT00892385
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT03168880
Drug: Paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
Trial: NCT03168880
Drug: Paclitaxel only
RxNorm normalized name: Paclitaxel only product
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01816997
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00053417
Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)
Trial: NCT00053417
Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP)
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)
Trial: NCT00053417
Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)
Trial: NCT03112863
Drug: Bakuchiol
RxNorm normalized name: Bakuchiol
DrugBank: Bakuchiol (DB16102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive bakuchiol
Trial: NCT03112863
Drug: Retinol
RxNorm normalized name: Retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive retinol
Trial: NCT02494479
Drug: Prurisol
RxNorm normalized name: chlorhexidine gluconate Mouthwash [Perisol]
DrugBank: Abacavir hydroxyacetate (DB12187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg tablet
Trial: NCT01116648
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01116648
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03015532
Drug: Bupivicaine HCl
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl without epinephrine
Trial: NCT03015532
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine, via injection
Trial: NCT02184195
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet -100mg
Trial: NCT02184195
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet-150mg
Trial: NCT02631525
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
Trial: NCT02631525
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia based on propofol
Trial: NCT03792815
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: busulfan 3.2mg/kg iv on day -8, -7, and -6,
Trial: NCT03792815
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: melphalan 50mg/m2/day i.v. on day -3 and -2
Trial: NCT03792815
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: etoposide 400 mg/m2 i.v. on day -5 and -4
Trial: NCT00941811
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Local Imiquimod three times weekly for 16 weeks
Trial: NCT01708603
Drug: 210 mg brodalumab
RxNorm normalized name: brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 210 mg brodalumab administered SC
Trial: NCT02354222
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02354222
Drug: Teneligliptin
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT01708603
Drug: 140 mg brodalumab
RxNorm normalized name: brodalumab 140 MG/ML
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140 mg brodalumab administered SC
Trial: NCT01708603
Drug: ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
Trial: NCT01038661
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV
Trial: NCT01038661
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV
Trial: NCT03934047
Drug: Tranexamic Acid 100 MG/ML
RxNorm normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
Trial: NCT03174847
Drug: Mineralocorticoid Receptor Antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medical treatment with MRA / amiloride
Trial: NCT01232647
Drug: Menatetrenone (MK4)
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (MK4) 45 mg daily